Systemic Lupus Erythematosus: Definitions, Contexts, Conflicts, Enigmas
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Systemic lupus erythematosus (SLE) is an inadequately defined syndrome. Etiology and pathogenesis remain largely unknown. SLE is on the other hand a seminal syndrome that has challenged immunologists, biologists, genetics, and clinicians to solve its nature. The syndrome is characterized by multiple, etiologically unlinked manifestations. Unexpectedly, they seem to occur in different stochastically linked clusters, although single gene defects may promote a smaller spectrum of symptoms/criteria typical for SLE. There is no known inner coherence of parameters (criteria) making up the disease. These parameters are, nevertheless, implemented in The American College of Rheumatology (ACR) and The Systemic Lupus Collaborating Clinics (SLICC) criteria to classify SLE. Still, SLE is an abstraction since the ACR or SLICC criteria allow us to define hundreds of different clinical SLE phenotypes. This is a major point of the present discussion and uses "The anti-dsDNA antibody" as an example related to the problematic search for biomarkers for SLE. The following discussion will show how problematic this is: the disease is defined through non-coherent classification criteria, its complexity is recognized and accepted, its pathogenesis is plural and poorly understood. Therapy is focused on dominant symptoms or organ manifestations, and not on the syndrome itself. From basic scientific evidences, we can add substantial amount of data that are not sufficiently considered in clinical medicine, which may change the paradigms linked to what "The Anti-DNA antibody" is-and is not-in context of the imperfectly defined syndrome SLE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Petri, M., Orbai, A., Alarcón, G. S., Gordon, C., Merrill, J. T., Fortin, P. R., Bruce, I. N., Isenberg, D., Wallace, D. J., Nived, O., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34473 · Cited by 5,322
Cervera, R., Piette, J., Font, J., Khamashta, M. A., Shoenfeld, Y., Camps, M. T., Jacobsen, S., Lakos, G., Tincani, A., Kontopoulou‐Griva, I., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10187 · Cited by 2,156 · cited 1×
““The anti-dsDNA antibody” exists and is described in context of bacterial and viral infections (27, 67– 69, 83–93), different cancer forms (94–107) and in autoimmune syndromes like autoimmune hepatitis (108), Sjøgren syndrome (109), SLE (33), or primary antiphospholipid syndrome (110) and other disorders.”
BackgroundDecoding the Patterns of Self and Nonself by the Innate Immune System
Medzhitov, R., & Janeway, C. A. (2002) · Science · doi:10.1126/science.1068883 · Cited by 2,154
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Complement fixation with cell nuclei and DNA in lupus erythematosus
Robbins, W. C., Holman, H. R., Deicher, H., & Kunkel, H. G. (1957) · Experimental Biology and Medicine · doi:10.3181/00379727-96-23545 · Cited by 302
Anti-DNA antibodies–quintessential biomarkers of SLE
Pisetsky, D. S. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.151 · Cited by 267
A DNA-Reacting Factor in Serum of a Patient with Lupus Erythematosus Diffusus.
Ceppellini, R., Polli, E., & Celada, F. (1957) · Experimental Biology and Medicine · doi:10.3181/00379727-96-23544 · Cited by 249
Compagno, M., Jacobsen, S., Rekvig, O., Truedsson, L., Heegaard, N., Nossent, J., Jönsen, A., Jacobsen, R., Eilertsen, G., Sturfelt, G., et al. (2013) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2013.765032 · Cited by 34 · cited 2×
“For non-SLE patients, anti-dsDNA antibodies seemed to represent a poor predictor for SLE within an observation period of 5 years (111, 112).”
BackgroundMethodSelf-citation
Cited by
Rekvig, O. P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01104 · Cited by 65
“Ludvik Fleck once said: “For the current state of knowledge remains vague when history is not considered, just as history remains vague without substantive knowledge of the current state” [(5), cited in (4)].”
BackgroundSelf-citationRekvig, O. P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.569234 · Cited by 42
Self-citationBiocompatible Nanovesicular Drug Delivery Systems with Targeting Potential for Autoimmune Diseases
Neupane, Y. R., Mahtab, A., Siddiqui, L., Singh, A., Gautam, N., Rabbani, S. A., Goel, H., & Talegaonkar, S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200523174108 · Cited by 21
Metadata
- Authors
- Rekvig, O. P.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-03-01
- Volume
- 9
- Pages
- 387-387
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2792098513
- Cited by
- 47
- References
- 8
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systemic Lupus Erythematosus: Definitions, Contexts, Conflicts, Enigmas. https://app.cochat.ai/papers/10.3389/fimmu.2018.00387
- The paper
- Rekvig, O. P. (2018). Systemic Lupus Erythematosus: Definitions, Contexts, Conflicts, Enigmas. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2018.00387
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.